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ABSTRACT
Translational frameshift errors are often deleterious
to the synthesis of functional proteins and could
therefore be promoted therapeutically to kill bacte-
ria. TrmD (tRNA-(N(1)G37) methyltransferase) is an
essential tRNA modification enzyme in bacteria that
prevents +1 errors in the reading frame during pro-
tein translation and represents an attractive potential
target for the development of new antibiotics. Here,
we describe the application of a structure-guided
fragment-based drug discovery approach to the de-
sign of a new class of inhibitors against TrmD in
Mycobacterium abscessus. Fragment library screen-
ing, followed by structure-guided chemical elabora-
tion of hits, led to the rapid development of drug-
like molecules with potent in vitro TrmD inhibitory
activity. Several of these compounds exhibit activity
against planktonic M. abscessus and M. tuberculo-
sis as well as against intracellular M. abscessus and
M. leprae, indicating their potential as the basis for a
novel class of broad-spectrum mycobacterial drugs.
INTRODUCTION
Mycobacteria are a group of diverse organisms that include
many important human pathogens such as Mycobacterium
tuberculosis, responsible for over 1.5 million deaths per year
from tuberculosis and Mycobacterium leprae, the causative
agent of leprosy, both associated with increasing rates of ac-
quired drug resistance (1,2). Furthermore, Mycobacterium
abscessus, a rapidly growing species of nontuberculous my-
cobacteria (NTM), has recently emerged as a major threat
to individuals with Cystic Fibrosis (CF) and other inflam-
matory lung conditions (3–5). Mycobacterium abscessus is
intrinsically resistant to most existing antibiotics and as a
consequence infections are associated with extremely high
rates of treatment failure and mortality (5). There is, there-
fore, an urgent unmet need to develop new antibiotics
against these mycobacterial infections. Hence, we examined
the possibility of promoting translational frameshift errors
as a novel approach to killing pathogenic mycobacteria.
Several structurally diverse, modified nucleosides found
at different locations of tRNAs help in the maintenance
of the reading frame and avoidance of translational frame-
shift errors. Many such nucleoside modifications are found
in regions near the anticodon, particularly at position 34
(the wobble position) and 37 (3′ and adjacent to the an-
ticodon) of tRNA (6,7). TrmD, tRNA-(N(1)G37) methyl-
transferase, catalyzes the methylation of G37 (Guanosine at
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position 37) in prokaryotic tRNAs (Figure 1A). This modi-
fied nucleotide N1-methylguanosine at position 37 (m1G37)
is present in tRNAs containing a G36G37 sequence in the
anti-codon region from all three domains of life, where G37
is the base adjacent to the anticodon at the 3′ end (6,8,9).
Mutations in trmD result in growth defects associated with
increased translational frameshifting leading to defective
protein production (7,9).
TrmD belongs to a distinct class of S-adenosyl-L-
methionine (SAM)-dependent methyltransferases known
as the SpoU-TrmD (SPOUT) RNA methyltransferase su-
perfamily or Class IV methyltransferases. Proteins belong-
ing to this family are structurally unique due to the absence
of a consensus methyltransferase fold. TrmD and other pro-
teins of the SPOUT family consist of a deep trefoil knot
architecture at the catalytic region, which provides an L-
shaped pocket for binding of SAM. In contrast, G37 methy-
lation in eukaryotes is carried out by the enzyme Trm5 be-
longing to the Class I methyltransferase family (10–12).
Previous research (11,13) has shown that TrmD and
Trm5 have distinct substrate requirements with RNA.
While Trm5 recognizes the overall L-shaped tertiary struc-
ture of tRNA possessing a G37 base, TrmD recognition in-
volves mainly the D stem and anticodon stem loop of tRNA
with G36G37 bases. Trm5 functions as a monomer and binds
to SAM at the Rossmann fold region of the active site, in
contrast to dimeric TrmD with a trefoil knot methyl donor
binding region. Further, SAM adopts a unique bent con-
formation in TrmD as compared to the extended conforma-
tion in Trm5 and many other canonical methyltransferases.
These distinct structural features, substrate requirements
and ligand binding conformations between TrmD and its
human ortholog provide the potential for designing novel
and selective inhibitors of bacterial TrmD (14). Further, a
recent study (15) in gram-negative bacteria, demonstrates
the crucial role played by m1G37 methylation of tRNA by
TrmD in determining the synthesis of membrane proteins
such as drug efflux pumps. This is achieved through regula-
tion of protein translation at proline codons near the start
of open-reading frames. Thus, the modification of tRNA
by TrmD appears to be a global determinant of mem-
brane protein synthesis at least in gram-negative bacteria
and therefore inhibition of TrmD greatly impairs the devel-
opment of drug resistance by sensitizing these organisms to
antibiotics (15).
Previous drug discovery efforts targeting TrmD in
Haemophilus influenzae (16) and Pseudomonas aeruginosa
(17) led to the development of selective inhibitors with po-
tent biochemical activity against TrmD isozymes in vitro.
However, these compounds in general only showed weak
antibacterial activity when profiled against a range of bac-
teria. We nevertheless wondered whether targeting TrmD,
using a structure-guided fragment-based strategy, with sys-
tematic testing of biochemical and antimicrobial activities
at each stage of iteration might prove successful in mycobac-
teria.
Fragment-based drug discovery (FBDD) is a promising
approach for the development of new drugs, whereby the
complexity of sampling chemical space is reduced by screen-
ing promiscuous small molecules (‘fragments’) for low affin-
ity in vitro interactions. Initial fragment hits usually exhibit
lower potency than the more complex drug-like molecules
found in typical high-throughput screening compound li-
braries. However, such fragments bind by making well-
defined and directional interactions, giving rise to highly
ligand efficient (LE) molecules. These fragments can then
be chemically optimized into lead candidates, thereby more
effectively exploring the chemical space available for bind-
ing to the target protein (18–21). In this work we validate
TrmD as a mycobacterial target and describe the applica-
tion of an FBDD approach to generate a new family of
small-molecule inhibitors of M. abscessus TrmD, having




Escherichia coli DH5, used for cloning, was grown in LB
Lennox (BD, Difco) medium at 37◦C. Mycobacterium ab-
scessus ssp. massiliense CIP108297 was grown in Middle-
brook 7H9-ADC broth (BD, Difco) supplemented with
0.05% Tween 80 or 7H11-ADC agar (BD, Difco) at 37◦C.
Kanamycin (Kan), streptomycin (Str) and hygromycin
(Hyg) were added to final concentrations of 200, 200 and
2000 g/ml, respectively. Homologous recombination at
the trmD locus of M. abscessus ssp. massiliense CIP108297
was performed using a mycobacterial recombinase-based
system in which the recombineering genes from mycobacte-
riophage Che9c (22) are expressed from the replicative plas-
mid pNitET-xylE-kan (a derivative of the pNitET-sacB-
kan plasmid (23) generated in-house in which the sacB gene
was replaced by the xylE colored marker) under control
of an isovaleronitrile-inducible promoter. Isovaleronitrile-
induced M. abscessus ssp. massiliense CIP108297 cells har-
boring pNitET-xylE-kan were electro-transformed with
∼300 ng of linear allelic exchange substrate consisting of
the streptomycin-resistance cassette from pHP45 flanked
by 1000 bp of DNA sequence immediately flanking the
start and stop codons of trmD, and double-crossover mu-
tants were isolated on Str-containing agar. Allelic replace-
ment leading to the complete deletion of the trmD locus was
checked by PCR using a pair of primers annealing outside
the linear allelic exchange substrate.
Plasmid pMV306H was constructed by replacing the
kanamycin-resistance cassette of pMV306hsp (an integra-
tive mycobacterial expression vector allowing for the ex-
pression of genes under control of the hsp60 promoter; Ad-
dgene plasmid # 26155) (24) by a hygromycin-resistance
cassette. pMV306H::trmD was generated by cloning the
PCR-amplified trmD gene from M. abscessus ssp. mas-
siliense CIP108297 in the HindIII site of pMV306H. All
primer sequences are shown in Supplementary Table S1.
Expression and purification of full-length M. abscessus
TrmD
Escherichia coli BL21 (DE3) strain containing AVA0421
plasmid with an N-His-3C Protease site-TrmD full-length
insert, kindly provided by the Seattle Structural Genomics
Consortium, (25) was grown overnight at 37◦C in LB-media
containing Ampicillin (100 g/ml). This seed stage culture
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Figure 1. (A) TrmD reaction scheme illustrated with a cloverleaf model of M. abscessus UGG isoacceptor tRNAPro. The modified Guanosine 37 base is
indicated in red circle and the chemical reaction, mediated by TrmD, leading to the synthesis of N1-methyl guanosine 37 is illustrated with corresponding
2-D chemical structures in black. The chemical structures of the methyl donor S-adenosyl-L-methionine, which in turn gets converted into S-adenosyl-
L-homocysteine, are shown in blue. (B) TrmD homodimer (PDB code 6NVR) with domain architecture illustrated. Protomers 1 and 2 are represented
in brown and green ribbon diagrams respectively. (C) TrmD protomer is coloured and illustrated based on secondary structure elements. The disordered
inter-domain linker is shown as black dotted lines.
was used to inoculate six shake flasks containing 1 l each
of 2XYT media with Ampicillin (100 g/ml) until optical
density (A600 nm) reached 0.6. The expression of recombi-
nant construct was induced by the addition of isopropyl -
D-1-thiogalactopyranoside (IPTG) to a final concentration
of 0.5 mM and further allowed to grow at 18◦C for 16 h.
Isolation of cells and lysis. Cells were harvested by cen-
trifugation at 4◦C for 20 min at 5000 g and the pellet was
re-suspended in buffer A (25 mM HEPES pH 7.5, 500 mM
NaCl, 5% glycerol, 10 mM MgCl2, 1 mM TCEP, 20 mM
imidazole). 0.1% Triton (Sigma), 10 g/ml DNaseI, 5 mM
MgCl2 and three protease inhibitor cocktail tablets (New
England Biolabs) were added to the cell suspension. The
cells were lysed in an Emulsiflex (Glen Creston) and clarified
the lysate by centrifugation at 4◦C for 40 min at 25 568 g.
Immobilized metal affinity chromatography. The clarified
lysate was filtered using a 0.45 m syringe filter and passed
through a pre-equilibrated (with buffer A), 10 ml pre-
packed nickel- sepharose column (HiTrap IMAC FF, GE
Healthcare). The column was washed with 5 column vol-
umes of buffer A and the bound protein was eluted as 4 ×
10 ml elutes using buffer B (25 mM HEPES pH 7.5, 500
mM NaCl, 5% glycerol, 1 mM TCEP, 500 mM imidazole).
The protein was analyzed on a 15% SDS-PAGE gel. Dialy-
sis: Elutes from Hi-Trap IMAC column were pooled, added
3C Protease in the ratio of 1:50 mg (protease: protein) and
subjected to dialysis against 2 l of buffer C (25 mM HEPES
pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM TCEP) overnight
at 4◦C.
Protein, after overnight dialysis and cleavage of N-His
tag, was passed through a pre-equilibrated (buffer A) 5 ml
HiTrap IMAC FF Nickel column (GE Healthcare).
Size exclusion chromatography. The flow through from the
above column was concentrated to 3 ml using a 10 kDa cen-
trifugal concentrator (Sartorius Stedim) and loaded onto
a pre-equilibrated (with buffer D: 25 mM HEPES pH 7.5,
500 mM NaCl, 5% glycerol) 120 ml Superdex200 16/600
column (GE Healthcare). 2 ml fractions were collected and
analyzed on a 15% SDS-PAGE gel. Fractions correspond-
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ing to pure TrmD protein were pooled and concentrated to
25 mg/ml, flash frozen in liquid nitrogen and stored at –
80◦C. Identity of the purified protein was further confirmed
by MALDI mass fingerprinting.
Crystallization of apo form of full-length M. abscessus TrmD
M. abscessus TrmD apo crystals were grown in 48-well sit-
ting drop plates (Swiss CDI) in the following condition: 0.08
mM Sodium cacodylate pH 5.8 to 6.8, 1–2 M ammonium
sulphate. 24 mg/ml of the protein in storage buffer (25 mM
HEPES pH 7.5, 500 mM NaCl, 5% glycerol) at drop ratio 1
l:1 l (protein:reservoir respectively) were set up and equi-
librated against 70 l reservoir.
Soaking of TrmD native crystals with fragments and ligands
Crystals for this experiment were grown at 19◦C in 48-well
sitting drop plates (Swiss CDI) in the following condition:
0.08 mM Sodium cacodylate pH 6.5 to 7.0, 1–2 M ammo-
nium sulphate, 20 mg/ml of the protein in storage buffer
(25 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol) at
drop ratio 1 l:1 l were set up and equilibrated against
250 l reservoir. Further, the crystals were picked and al-
lowed to soak in a 4 l drop containing reservoir solution
and 10 mM fragments/compound (in DMSO) which was
then equilibrated against 700 l of the corresponding reser-
voir solution overnight at 19◦C in 24-well hanging drop va-
por diffusion set up.
Co-crystallization of TrmD protein with SAM/ SAH/ AW6/
AW7
2–5 mM final concentration of compound in DMSO/water
was added to 20 mg/ml of TrmD protein, mixed and incu-
bated for 2 h on ice. Crystals were grown in the following
condition: 0.08 mM Sodium cacodylate pH 6.5 to 7.0, 1–2
M Ammonium sulphate or in sparse matrix screens: Wiz-
ard 1&2 (Molecular Dimensions), Wizard 3&4 (Molecular
Dimensions), JCSG +Suite (Molecular Dimensions). The
crystallization drops were set up at a protein to reservoir
drop ratio of 0.3 l:0.3 l, in 96-well (MRC2) sitting drop
plate, using mosquito crystallization robot (TTP labtech)
and the drops were equilibrated against 70 l of reservoir
at 19◦C.
X-ray data collection and processing
The TrmD apo/ligand-bound crystals were cryo-cooled in
mother liquor containing 27.5% ethylene glycol. X-ray data
sets were collected on I04, I02, I03, I04-1 or I24 beamlines
at the Diamond Light Source in the UK, using the rota-
tion method at wavelength of 0.979 Å, Omega start: 0◦,
Omega Oscillation: 0.1–0.2◦, Total oscillation: 210–240◦,
total images: 2100–2400, Exposure time: 0.05–0.08 s. The
diffraction images were processed using AutoPROC (26),
utilizing XDS (27) for indexing, integration, followed by
POINTLESS (28), AIMLESS (29) and TRUNCATE (30)
programs from CCP4 Suite (31) for data reduction, scaling
and calculation of structure factor amplitudes and inten-
sity statistics. All TrmD crystals belonged to space group
P212121 and consisted of two protomers in the asymmetric
unit.
Structure solution and refinement
The M. abscessus TrmD Apo structure was solved by molec-
ular replacement using PHASER (32) with the atomic coor-
dinates of M. abscessus TrmD at 1.7 Å (PDB entry: 3QUV
Seattle Structural Genomics Consortium for Infectious
Diseases) as search model and TrmD ligand bound struc-
tures were solved by molecular replacement with the atomic
coordinates of the solved M. abscessus TrmD Apo structure
(PDB entry: 6NVR) as search model. Structure refinement
was carried out using REFMAC (33) and PHENIX (34).
The models obtained were manually re-built using COOT
interactive graphics program (35) and electron density maps
were calculated with 2|Fo| – |Fc| and |Fo| – |Fc| coefficients.
Positions of ligands and water molecules were located in dif-
ference electron density maps and OMIT difference maps
|mFo − DFc| (36) were calculated and analysed to further
verify positions of fragments and ligands.
Differential scanning fluorimetry (DSF)
DSF were carried out in a 96-well format with each well
containing 25 l of reaction mixture of 10 M TrmD pro-
tein in buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5%
glycerol), 5 mM compound, 5% DMSO and 5× Sypro or-
ange dye. Appropriate positive (Protein, DMSO and SAM)
and negative (Protein, DMSO only) controls were also in-
cluded. The measurements were performed in a Biorad-
CFX connect thermal cycler using the following program:
25◦C for 10 min followed by a linear increment of 0.5◦C ev-
ery 30 s to reach a final temperature of 95◦C. The results
were analyzed using Microsoft excel.
Isothermal titration calorimetry (ITC)
ITC experiments to quantify binding of ligands to TrmD
were done as described in (37) using Malvern MicroCal
iTC200 or Auto-iTC200 systems at 25◦C. Titrations con-
sisted of an initial injection (0.2 l), discarded during data
processing, followed by either 19 (2 l) or 39 (1 l) injec-
tions separated by intervals of 60–150 s duration. Protein
was dialysed overnight at 4◦C in storage buffer (M. absces-
sus TrmD: 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glyc-
erol; M. tuberculosis TrmD: 25 mM HEPES pH 7.5, 500
mM NaCl). Sample cell and syringe solutions were pre-
pared using the same storage buffer, with a final DMSO
concentration of 2–10% according to ligand solubility in
the buffer. TrmD concentrations of either 33 or 100 M
were used, with ligand to protein concentration ratios rang-
ing from 10 to 20:1. Control titrations without protein were
also performed and subtracted from ligand to protein titra-
tions. Titrations were fitted with Origin software (Origin-
Lab, Northampton, MA, USA), using a one-site binding
model with N fixed to 1 only for weakly binding ligands.
Titrations were typically performed once (n = 1), with mul-
tiple isotherms obtained (n > 1) for key compounds of in-
terest. Kd values are reported to two significant figures. Er-
ror provided by Origin software due to model fit is reported
when n = 1, whereas standard deviation is reported when
n > 1.
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Chemical synthesis of compounds
The compounds AW1-7 were synthesised according to the
procedures described in the supporting information. A
more in-depth discussion around the medicinal chemistry
strategy for fragment merging and lead compound develop-
ment is described in a corresponding publication by White-
house et al. (37). The compounds AW1-7 are listed in this
publication as follows: AW1 (Compound 23), AW2 (Com-
pound 24f), AW3 (Compound 26f), AW4 (Compound 28),
AW5 (Compound 29a), AW6 (Compound 31a) and AW7
(Compound 29d).
Biochemical activity assays
Assays for quantifying TrmD methylation reactions were
carried out in 20 l reactions consisting of 6.25 M SAM,
0.1 M TrmD and 6.25 M tRNAProUGG in the presence
of 0–500 M compounds in serial dilutions using assay
buffer containing 50 mM Tris–HCl pH 7.5, 10 mM MgCl2,
24 mM NH4Cl, 5% DMSO and 1 mM DTT in nuclease
free water. tRNA sequences were identified from the M.
abscessus genome sequence using tRNAscan-SE algorithm,
(38,39). The substrate M. abscessus tRNAProUGG for the
assay, having the sequence 5′-CGGGGUGUAGCGCAG
CUUGGUAGCGCAUCCGCUUUGGGAGCGGAG
GGUCGCAGGUUCAAAUCCUGUCACCCCGA-3′,
was purchased commercially from Integrated DNA tech-
nologies (USA). The reactions were carried out for 1 h at
room temperature followed by addition of 20 mM EDTA
to stop the reactions. Each of the 20 l samples were
diluted ten-fold with the UPLC mobile phase solvent A
(0.1% formic acid in water), centrifuged for 10 min at
13 000 g, to remove any precipitates, and the supernatant
was aliquoted into 96-well plates. 40 l samples were
then injected into Acquity UPLC (Waters) T3 1.8 M
column and eluted using a gradient elution consisting of
Mobile Phase A: 0.1% formic acid in water and mobile
phase B: 0.1% formic acid in 100% methanol for 4 min.
The absorbance was monitored using a photodiode array
(PDA) detector (Waters) at wavelength range of ƛ: 220–500
nm. All reactions were carried out in triplicate. The blank
corrected data were analyzed using Microsoft excel and
non-linear regression analysis for IC50 determination
were done using GraphPad prism version 7.00, GraphPad
Software, La Jolla, CA, USA.
Mycobacterial strains used and MIC measurements
Mycobacterium abscessus ssp. abscessus (ATCC 19977)
transformed with pmv310 plasmid expressing Lux ABDCE
operon, grown in Middlebrook 7H9 broth supplemented
with ADC (Sigma, UK). All the other NTM strains are
clinical isolates. Minimum inhibitory concentrations (MIC)
were determined for mycobacteria according to the Clinical
and Laboratory Standards Institute (CLSI) method M07-
A9. Briefly, mycobacteria were grown to optical density
(A600 nm) of 0.2–0.3 in liquid culture and 1 × 105 bacteria
were added to each well of 96-well plates containing se-
rial dilutions of compound (400, 200, 100, 50, 25, 12.5, 6.3,
3.1, 1.6, 0.8, 0.4, 0 M), in triplicate wells per condition,
and incubated at 37◦C until growth was seen in the con-
trol wells. MIC measurements using M. tuberculosis H37Rv
were performed as reported in (37). M. tuberculosis H37Rv
was grown in Middlebrook 7H9 base containing 14 mg/l di-
palmitoyl phosphatidylcholine (DPPC), 0.81 g/l NaCl, 0.3
g/l casitone, and 0.05% Tyloxapol. H37Rv was grown and
diluted to a similar inoculum size as mentioned above prior
to exposure to serial dilutions of compounds (starting at 100
M), and the plates were incubated at 37◦C for 2 weeks. The
MIC value was determined as the last well which showed no
bacterial growth.
CRISPR–dCas9 knockdown in M. abscessus
The dCas9 encoding plasmid (pTetInt-dcas9-Km) and the
second vector containing the sgRNA cassette (pGRNAz)
were derived from the tetracycline inducible CRISPr In-
terference system of Choudhary et al. (40) and optimized
for M. abscessus ATCC19977. The 20 nucleotides guides
targeting yidC(MAB 4953c) and trmD(MAB 3226c) were
annealed and cloned in between sphI and aclI of the
pGRNAz. As a control the pGRNAz was left empty.
The CRISPr-I containing strains were cultivated in Mid-
dlebrook 7H9 broth supplemented with 1× ADC, 0.05%
tween80 and 0.5% glycerol, hygromycin 1 mg/ml and zeocin
300 g/ml. The cultures were inoculated at 10∧6CFU/ml
from an exponentially grown pre-cultures. The AW7 com-
pound and doxycycline were added or not at a concentra-
tion of 25M and 1.5625, 6.25, 25 or 100 ng/ml respectively.
The OD600 was measured and the CFU counted at 72 h.
Macrophage infection study
Blood samples were donated by healthy volunteers who
had undertaken informed consent in accordance with lo-
cal Research Ethics Committee approval. Peripheral blood
mononuclear cells were isolated from citrated peripheral
blood samples by density gradient separation using Lym-
pholyte (Cedarlane Labs), and subsequent CD14+ posi-
tive selection using the MACS Miltenyi Biotec Human
CD14 microbead protocol (Miltenyi Biotec). CD14+ cells
were differentiated into macrophages using recombinant
human granulocyte-macrophage colony-stimulating factor
(200 ng/ml GM-CSF) and recombinant human interferon
gamma (50 ng/ml IFN ) (Peprotech) in standard tissue
culture DMEM media containing fetal calf serum, peni-
cillin and streptomycin. Following removal of antibiotics,
macrophages were infected at a multiplicity of infection of
10:1 with M. abscessus 19977 for 2 h, washed in sterile phos-
phate buffered saline, and then incubated in DMEM me-
dia with FCS and 25 M of compound for 24 and 48 h.
At the given time points, supernatant was saved for cell
cytotoxicity studies, and M. abscessus survival within the
macrophages calculated by macrophage lysis in sterile wa-
ter, and colony forming unit calculation on Columbia Blood
Agar plates (VWR BDH).
Cytotoxicity
Lactate dehydrogenase (LDH) was measured as a
biomarker for cellular cytotoxicity using the Pierce
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LDH Cytotoxicity Assay Kit. Cell supernatant was mea-
sured at 2, 24 and 48 h post-infection according to the kit
protocol.
Nude mouse derived M. leprae
Mycobacterium leprae (isolate Thai-53) was maintained in
serial passage in the foot pads of athymic nude mice (En-
vigo, USA). Mice were inoculated in the plantar surface of
both hind feet with 5 × 107 fresh, viable nude mice derived
M. leprae. When the mouse foot pads became moderately
enlarged (at ∼5–6 months), they were harvested for intra-
cellular M. leprae as described previously (41), washed by
centrifugation, re-suspended in medium, enumerated by di-
rect count of acid fast bacilli according to Shepard’s method
(42), held at 4◦C pending quality control tests for contami-
nation and viability (41). Freshly harvested bacilli were al-
ways employed in experiments within 24 h of harvest.
M. leprae axenic culture
Freshly harvested nude mouse foot pad derived M. leprae
were suspended in modified 7H12 medium, AW7 was added
at different concentrations (100–6.25 M) and were incu-
bated for 7 days at 33◦C. Media only and rifampin (Sigma,
USA) at 2.4 M were used as negative and positive controls.
Following incubation aliquots of AW7 treated and control
M. leprae were processed for radiorespirometry (RR) as de-
scribed previously (43).
M. leprae macrophage culture
Bone marrow cells were obtained aseptically from both
femurs of female BALB/c mice and cultured on plastic
cover slips in Dulbecco modified Eagle’s medium (DMEM,
Life Technologies, USA) supplemented with 10% (v/v) fetal
calf serum (Life Technologies), 25 mM/l HEPES (Sigma,
USA), 2 mM/l glutamine (Sigma, USA), 50 g/ml ampi-
cillin (Sigma, USA) and 10 ng/ml of recombinant murine
macrophages colony stimulating factor (R&D Systems,
USA) for 6–7 days at 37◦C and 5% CO2. The cells were
infected with freshly harvested nude mice foot pad derived
live M. leprae at a multiplicity of infection (MOI) of 20:1
overnight at 33◦C and then washed to remove extracellular
bacteria. AW7 was added at different concentrations (100–
6.25 M) and the cells were incubated for 7 days at 33◦C.
Media only and rifampicin at 2.4 M were used as neg-
ative and positive controls. AW7 treated and control cells
were lysed with sodium dodecyl sulfate (SDS, 0.1% w/v,
Sigma, USA) and the intracellular M. leprae processed for
radiorespirometry (44).
Radiorespirometry
Metabolism of a suspension of M. leprae was measured by
evaluating the oxidation of 14C-palmitic acid to 14CO2 by
radiorespirometry as described previously (45). Levels of
captured 14CO2 is proportional to the rate of 14C-palmitic
acid oxidation and used as an indicator of M. leprae viabil-
ity. In the present study the seventh day cumulative counts
per minute (CPM) were recorded and percentage inhibition
of metabolism determined as compared to no drug con-
trol. Statistical significance between treatment groups and
no drug control were determined by Student’s t-test and P
< 0.05 is considered as significant.
RESULTS
TrmD is essential for viability of M. abscessus
Although previous transposon mutagenesis studies have
suggested that trmD is essential in M. tuberculosis (46–48),
confirmation of essentiality in M. abscessus was previously
lacking. Three initial attempts to disrupt the trmD gene of
M. abscessus by homologous recombination using a recom-
bineering approach resulted in no colony growth. To con-
firm that trmD gene is essential for M. abscessus viability, al-
lelic replacement experiments were repeated in merodiploid
M. abscessus expressing a second copy of the trmD gene
from the integrative plasmid pMV306H::trmD, or in empty
vector controls. Analysis of over 100 candidate mutants
in each background, from two independent experiments,
showed that endogenous chromosomal trmD could only be
knocked-out in the presence of an extra-copy of the gene
(Supplementary Figure S1), confirming trmD essentiality in
M. abscessus.
M. abscessus TrmD: overall structure and ligand binding
We determined the crystal structures of M. abscessus TrmD
in apo form at 1.60 Å resolution (PDB code: 6NVR), as well
as in complex with SAM and S-adenosyl-L-homocysteine
(SAH) at 1.67 and 1.48 Å resolution respectively (PDB
codes: 6NW6 and 6NW7). Data collection and crystallo-
graphic statistics are given in Supplementary Table S2. The
crystals belong to space group P212121 and consist of a ho-
modimer in the asymmetric unit. Each non-crystallographic
2-fold symmetry-related protomer of TrmD interacts in an
antiparallel manner and consists of two domains: a larger
N-terminal domain spanning residues 1–161 and a smaller
C-terminal helical domain (177–242) connected by a flexible
inter-domain linker. The two domains of the individual pro-
tomers do not contact each other and the inter-domain re-
gion is largely disordered, with residues 162–177 not clearly
visible in the apo structure (Figure 1B and C).
The SAM binding region of TrmD is located at the base
of the N-terminal domain and consists of a deep trefoil knot
architecture, made of three distinct untwisted loop regions.
The trefoil knot of M. abscessus TrmD is made up of a cover
loop spanning residues 84TPAG87 between strand 3 and
helix 4 leading to the wall loop at the edge of the methio-
nine pocket containing residues 109GRYEGID115 between
4 and helix 5. This loop then crosses over to form the
bottom loop with residues 132–140 that encompasses the
SAM adenine ring between strand 5 and helix 6 (Figure
2A and B). SAM and SAH occupy the deep trefoil-knot ac-
tive site at the base of the N-terminal region and adopt an
L-shaped bent conformation as previously observed with
other TrmD orthologs (49,50). Both SAM and SAH form
an extensive hydrogen-bonding network in this region along
with hydrophobic and -interactions as shown in Figure
2B & Supplementary Figure S2. The adenine ring of SAM
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Figure 2. (A) Structural superposition of TrmD apo form (white) and TrmD SAM bound form (light blue), PDB codes 6NVR and 6NW6 respectively
(B) the trefoil-knot active site of TrmD involving: cover loop (residues 84–87) shown in dark blue and bottom loop (residues 132–140) in magenta and
wall loop (residues 109–115) in green and the conformational flip of the wall loop (residues 109GRYEGID115) upon SAM (light blue stick) binding are
illustrated. The residues corresponding to each loop region are also shown as line representation. (C) Three representative fragment hits from each cluster,
fragment 14 (PDB Code 6QOK) coloured in blue, fragment 20 (PDB Code 6QOQ) in green and fragment 8 (PDB Code 6QOE) in salmon respectively,
occupying the TrmD SAM binding site. Major Hydrogen bonds and electrostatic interactions are depicted in black and purple dotted lines respectively.
(D) Hot spot map contoured at 14 of TrmD active site superposed with crystal structure of TrmD in complex with merged compound AW1 (light blue
stick). Donor, acceptor and hydrophobic regions of the map are depicted as blue, red and yellow regions respectively. Amino acid residues contributing
towards interactions in each hotspot map region are shown as brown stick representation. The arrows indicate two potential ways of fragment elaboration.
and SAH is sandwiched between the cover loop and bot-
tom loop of the knot with the adenine N1 and N7 forming
hydrogen-bond contacts with the backbone amide-nitrogen
atoms of Ile133 and Leu138 respectively, while the amino
nitrogen forms additional hydrogen bonding contacts with
the backbone carbonyl oxygen atoms of Gly134 and Tyr136
of the bottom loop (Figure 2B and Supplementary Figure
S2).
The ribose and methionine moieties of SAM and SAH
interact with the wall and bottom loops of the knot. The
hydroxyl oxygen atom (O2′) of the ribose ring forms a hy-
drogen bond with the backbone amide of Gly109. The me-
thionine and homocysteine moieties further extend into the
active site groove formed between the cover and wall loops,
making further hydrogen-bonding interactions with water
molecules in this region (Figure 2B and Supplementary Fig-
ure S2).
A structural superposition of the apo and SAM bound
forms of TrmD reveals the wall loop undergoing a switch
in conformation leading to a movement of about 5 Å, when
measured at the C of Tyr111, to the outer edge of subunit
A. This conformational flip of the wall loop from apo form
to SAM-bound form and the subsequent change in posi-
tions of residues 110–113 help to accommodate the methio-
nine moiety of the methyl donor (Figure 2A and B).
Fragment screening, hit validation and clustering of frag-
ments
Having examined the conformational changes and bind-
ing interactions at the M. abscessus TrmD catalytic site,
we initiated a structure-guided FBDD effort targeting M.
abscessus TrmD by screening an in-house library of 960
small molecule fragments. The preliminary screening was
8106 Nucleic Acids Research, 2020, Vol. 48, No. 14
performed using differential scanning fluorimetry (DSF),
resulting in 53 hits within a thermal shift cut-off value of
3 standard deviations from the negative control (the TrmD
protein and DMSO in the absence of ligand). These hits
were then selected for validation by X-ray crystallography.
Apo crystals of M. abscessus TrmD were soaked with each
of the 53 fragments in independent experiments. The result-
ing crystal structure determinations allowed characteriza-
tion of the binding modes of 27 fragments (Supplementary
Figure S3).
All of the 27 fragments validated by X-ray crystallogra-
phy were found to occupy the TrmD SAM site. These frag-
ments can be clustered into three groups based on their
binding mode at this site (Figure 2C and Supplementary
Figure S3). Cluster 1 consists of 12 fragments that bind
exclusively to the sub-pocket that accommodates the ade-
nine ring of SAM, engaging residues within the cover and
bottom loops of the trefoil knot. These fragments recapit-
ulated many of the hydrogen bonding and -interactions
of the SAM adenine moiety, as shown in the example
(Figure 2C and Supplementary Figure S3). These interac-
tions include hydrogen-bond contacts to the side chain of
Ser132, which in turn adopts a dual conformation, and
to the backbone amides of Ile133, Gly134, Tyr136 and
Leu138.
The second cluster consists of 12 further fragments that
occupy the entire adenosine region of the TrmD active site,
thus extending from adenine towards the ribose-binding
pocket of the active site. These fragments, in addition to re-
taining several adenine moiety contacts, also interact with
the wall loop residues, forming hydrogen bonds to the back-
bone amides of Tyr111 and Gly109 and water-mediated hy-
drogen bonds as shown in the example (Figure 2C and Sup-
plementary Figure S3).
Cluster 3 consists of three fragments that extend beyond
the TrmD adenosine site, thus reaching the methionine-
binding region of the pocket. One of these fragments, Frag-
ment 8 stretched further into the groove formed between
the cover and wall loops of the trefoil knot, thus engaging
additional hydrogen bonding contacts with the side chain
of Thr84 and the backbone amide of Gly109 in this region
(Figure 2C and Supplementary Figure S3).
Fragment merging and hotspot mapping for chemical elabo-
ration
Two of the above 27 fragment hits, fragments 23 (Kd 0.17
mM, LE 0.37) and 24 (Kd 0.26 mM, LE 0.41), were chosen
for further chemical development by a fragment-merging
strategy. The choice of fragments for subsequent chemical
optimization was based on a number of criteria, includ-
ing binding affinity, ligand efficiency, synthetic tractability
and their ability to make key binding interactions at the
TrmD SAM binding site. Fragment 23 occupies the adeno-
sine binding region of the TrmD AdoMet site, with its pyra-
zole ring making hydrogen bond contacts to the backbone
amides of Tyr136 and Leu138 and the amino group making
further hydrogen bonds with the backbone carbonyl oxygen
of Gly134 and the side chain of Ser132, respectively. The 4-
methoxyphenyl ring of the fragment extends into the ribose
binding site, engaging hydrophobic and -interactions with
the residues of the cover loop (Figure 3A, Supplementary
Figures S3 and S4).
The indole ring of Fragment 24 also occupies the ribose
pocket where it forms a water-mediated interaction with the
backbone amide nitrogen of Leu138. The 4-methoxyphenyl
and indole ring systems of Fragments 23 and 24 overlap per-
fectly, while the 6-boronic acid group of fragment 24 par-
tially extends into the SAM adenine pocket and makes hy-
drogen bonds with the backbone amides of residues Tyr136
and Leu138 and further water-mediated hydrogen bond
contacts to the backbone amides of Val131, Ile133, Gly134
and the side chain hydroxyl group of Ser132 (Figure 3A and
Supplementary Figure S3). Compound AW1 (Kd 0.11 mM,
LE 0.36, IC50 0.23 mM), formed by merging the two frag-
ments, adopts a similar conformation to that of the original
fragments in the TrmD SAM site, as shown in Figures 3B,
C and Supplementary Figure S4, thereby providing a new
chemical scaffold for further structure-guided development.
To aid the structure-guided lead discovery, we exam-
ined the ligand binding propensities of TrmD using hotspot
mapping, a computational approach developed by Ran-
doux, Blundell, and colleagues (51). Hotspots are areas
within the protein that provide relatively large contributions
to the overall binding affinity of ligands (52,53).
While the observed fragment hits and the correspond-
ing merged compound AW1 satisfy many of the predicted
protein-hotspot interactions, the map also suggested fur-
ther potential interactions that could stabilise elaborated
fragments. As shown in Figure 2D, AW1 occupies Hotspot
1 at the base of the TrmD active site, where it satisfies the
hydrogen-bond donor requirements by interacting with the
backbone amide oxygen atoms of Gly134 and Tyr136. The
merged compound AW1 also orients its pyrazole nitrogen
atom in the acceptor map in this region where it forms a
hydrogen bond with the backbone NH of Leu138 (Figures
2D and 3B). The compound could be elaborated further
towards the methionine end of the active site and by fur-
ther extension to the second hotspot region at the top of
the active site. The second hotspot is characterized by a
large hydrophobic patch surrounded by the acceptor region
mediated by the backbone amide group and side chain of
Glu180. A second approach to fragment elaboration would
be by growing further upwards from the hydrophobic region
of Hotspot 2 over to the donor region mainly mediated by
the backbone oxygen atom and side chains of Glu112 as il-
lustrated in Figures 2D and 3B.
Structure-based lead optimization of merged compounds
Structure-guided elaboration of the merged compound
AW1 (Kd 0.11 mM, LE 0.36, IC50 0.23 mM) was performed,
initially utilizing the indole nitrogen as a vector for growth.
While the detailed medicinal chemistry strategy of all the
compounds and intermediates are described separately (37)
and in supporting information (Schemes 1–4 and Supple-
mentary Table S3), in this section we illustrate the key fea-
tures in the fragment hit to lead optimization of TrmD in-
hibitors. The addition of a 2-picolyl moiety successfully in-
creased the affinity of AW1 by an order of magnitude in
compound AW2 (Kd 12 M, LE 0.30, IC50 33 M) (Table
1 and Supplementary Figures S5 and S6). The methylene
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Figure 3. Fragment merging approach. (A) Structural superposition of TrmD (gray) in complex with fragments 23 (green) and 24 (beige) – PDB Codes
6QOT and 6QOU, showing binding mode and interactions at the SAM site (B) merged compound AW1 (light blue), PDB Code 6QQS, showing binding
mode at the SAM site. The corresponding amino acid interactions are illustrated in dotted lines and (C) the overall scheme of fragment merging.
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linker attached to the indole nitrogen of AW2 allowed the
added pyridyl ring to occupy the region defined by Pro85,
Glu112, Val137, Arg154 and Glu180 (Figure 4A).
The affinity of AW2 was further improved by the addition
of a nitrile group on the 4-position of its pyrazole ring, ex-
tending into the narrow space between residues 83PTP85 of
the cover loop and 131VSI133 of the bottom loop respectively
(Figure 4A, B and Supplementary Figure S4). AW3 (Kd 0.50
M, LE 0.36, IC50 0.31 M) was a significant improvement
on AW2, with the addition of two heavy atoms affording
a 25-fold decrease in Kd (12–0.50 M), increasing the lig-
and efficiency to the level of the original merged compound
AW1 (0.36), and a 100-fold decrease in IC50 (33 to 0.31 M)
(Table 1 and Supplementary Figures S5 and S6). The X-ray
crystal structure of TrmD in complex with AW3 shows that
the original fragment contacts have been retained, with the
AW3 aminopyrazole ring orienting itself in a similar man-
ner to AW1 and retaining its hydrogen bonding contacts to
the side chain of Ser132 and backbones of Gly134, Tyr136
and Leu138. In addition, the nitrile group of AW3 seems to
have strengthened the interactions at the active site region
between residues 83PTP85 and 131VSI133 by engaging in an
additional hydrogen bond contact with the backbone NH
of Ile133 (Figure 4B).
Further elaboration was carried out from the 5-position
of the pyridyl ring of AW3 through the attachment of a
pyrrolidinyl ring via another methylene linker, with AW4
(Kd 92 nM, LE 0.34) affording an additional 5-fold im-
provement in affinity (Table 1 and Supplementary Figures
S5 and S7). Modification of the scaffold of AW4 by replace-
ment of its pyridyl ring with a phenyl ring in AW5 (Kd 27
nM, LE 0.34, IC50 30 nM) was tolerated with a >3-fold im-
provement in affinity (92–27 nM) and an increase in ligand
efficiency (0.32–0.34) (Table 1 and Supplementary Figure
S5 and S7). The X-ray crystal structure of AW5 shows the
pyrrolidinyl ring occupying the binding site in two confor-
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Figure 4. X-ray crystal structure of TrmD (grey) in complex with compounds (A) AW2, PDB Code 6QQX (B) AW3, PDB Code 6QQY (C) AW5 at
protomer 1, PDB Code 6QR6, (D) AW5 at protomer 2, PDB Code 6QR6, (E) AW6, PDB Code 6QR5 and (F) AW7, PDB Code 6QR8, showing binding
mode at the SAM site. The corresponding amino acid interactions are illustrated with polar hydrogen bond interactions and -interactions in black and
purple dotted lines respectively. The TrmD protein is shown as white cartoon model with the interacting amino acid residues in grey lines, the compounds
at the active site are represented in light blue stick model with the corresponding Sigma A-weighted mFo – dFc omit maps in grey mesh representation.
The 2D chemical structures of each compound and the corresponding affinity (Kd), ligand efficiency (LE) and inhibition data (IC50) are also shown in the
inset in dark blue.
mations, depending on the active site, thereby engaging ei-
ther Glu112 or Glu180 in an electrostatic interaction (Fig-
ure 4C, D and Supplementary Figure S4). The removal of
the nitrile group on the pyrazole ring of AW5 in compound
AW6 (Kd 0.49 M, LE 0.31, IC50 1.4 M) (Table 1 and
Supplementary Figures S5 and S7), had a detrimental im-
pact on both affinity and performance in the biochemical
assay, demonstrating the importance of extension of this
substituent into the cavity between residues 83PTP85 of the
cover loop and 131VSI133 of the bottom loop (Figure 4E and
Supplementary Figure S4). Exploration of the active site re-
gion bordered by the Ala176 to Glu180 loop through re-
placement of the pyrrolidinyl ring of AW5 with an N-methyl
piperazinyl motif in AW7 (Kd 73 nM, LE 0.30, IC50 69 nM)
showed a slight worsening of both affinity and IC50 (Ta-
ble 1 and Supplementary Figures S5 & S8), possibly due to
the slight change (0.3 Å) in the position of the nitrile group
in comparison to that of AW5, thereby diminishing the hy-
drogen bonding contact with the backbone amide of Thr84
(Figure 4F, Supplementary Figures S4 and S9).
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Anti-mycobacterial activity of TrmD lead compounds
The fragments and developed compounds were then ex-
amined for their ability to inhibit bacterial growth. While
the initial fragment hits of TrmD and the early stage com-
pounds elaborated from the fragments exhibited low lev-
els of growth inhibition up to 250 M (data not shown)
compounds in later stages of development showed promis-
ing activity against M. abscessus and M. tuberculosis (Ta-
ble 2). Most of the lead TrmD compounds exhibited much
greater inhibition against M. tuberculosis than M. abscessus
(Table 2). Surprisingly, AW6, in which the nitrile group of
AW5 was removed, despite being the lesser active lead com-
pound in the in vitro TrmD assays, showed similar MICs
when compared to the other two compounds. Additionally,
the replacement of the pyrrolidinyl ring of AW5 with an
N-methyl piperazinyl motif in AW7 afforded a 2-fold im-
provement compared to AW5 in the MIC against M. tuber-
culosis, although not against M. abscessus (Table 2). M. tu-
berculosis TrmD in vitro binding affinities subsequently de-
termined for AW6 (Kd 0.90 M) and AW7 (Kd 0.33 M)
(Supplementary Figure S8) were in keeping with the cor-
responding MIC values, thereby supporting the applicabil-
ity of this lead series to TrmD orthologs from mycobac-
teria other than M. abscessus. We therefore tested AW6
and AW7 on a wider panel of NTMs including axenically-
maintained M. leprae and the compounds show inhibitory
activity against these bacteria (Table 2 and Supplementary
Figure S10). Given the high percentage sequence identity
of TrmD across various mycobacterial species (Supplemen-
tary Figure S11), the variation in MIC observed for our lead
compounds is likely to reflect differential permeability, re-
tention and metabolism of compounds (54,55).
Assessment of cytotoxicity and on-target activity of TrmD
inhibitors
We assessed the cytotoxicity effect of AW6 and AW7 us-
ing lactate dehydrogenase (LDH) release assay. It was ob-
served that at or below a concentration of 150 M, neither
compound caused cellular toxicity on human macrophages
(Supplementary Figure S12).
Further, to determine whether the anti-mycobacterial ac-
tivity of our compounds was directly related to TrmD in-
hibition and not caused by an off- target effect, we gener-
ated a Tet- inducible CRISPR-dCas9 system in M. absces-
sus, to tunably knockdown selected protein expression. In-
cremental silencing of TrmD, achieved through exposure to
increasing concentrations of doxycycline, resulted in M. ab-
scessus to become progressively more sensitive to AW7. Fur-
ther, this effect was not seen in bacteria expressing gRNA
targeting another essential gene (yidC) or an empty vector
control (Figure 5C), thereby confirming target engagement
TrmD inhibitors kill intracellular M. abscessus and M. leprae
The compounds were then evaluated in M. abscessus-
infected human macrophages. Both compounds showed in-
hibitory activity in the macrophage infection model, with
AW7 performing better than AW6 in the in vitro assays. At
25 M AW6 showed a ∼82% decrease in CFUs while AW7
at the same concentration showed a 95% reduction in CFUs
compared to the no drug control after 48h incubation (Fig-
ure 5A).
The best lead molecule (AW7) was further tested against
M. leprae maintained intracellularly in murine bone mar-
row macrophage. As a proxy for mycobacterial viability, rel-
ative inhibition of -oxidation rates were measured using
a radiorespirometry assay to track the metabolism of 14C-
palmitic acid to 14CO2 after 7 days of incubation (45). We
found that AW7 had considerable inhibitory effect against
M. leprae, being able to inhibit -oxidation by over 50% at
a concentration as low as 6.2 M (Figure 5B).
DISCUSSION
Most current antibiotics targeting protein synthesis act ei-
ther by interacting with ribosomal sub-units (for example
aminoglycosides, tetracyclines, and macrolides) or via in-
hibiting mRNA synthesis (rifamycins) and elongation (acti-
nomycin) (56), to which many clinically relevant bacte-
ria have developed resistance. However, other unexplored
mechanisms exist to disrupt protein synthesis, including by
promoting frame-shift translational errors. We have focused
on targeting TrmD (tRNA-(N(1)G37) methyltransferase),
an essential tRNA modification enzyme in bacteria that
methylates the guanosine base at position 37 of tRNAs con-
taining G36G37 bases at the anti-codon region to prevent
frame-shifting. Inhibition of TrmD will therefore promote
defective protein synthesis leading to cell death. Until now,
very few inhibitors have been developed against it and those
exhibit generally low bactericidal activity. Our study pro-
vides proof of concept that a fragment-based approach can
be successfully used to target mycobacterial tRNA modifi-
cation, delivering a new class of antibiotics with potent bac-
tericidal activities.
Fragments are powerful chemical tools that have huge
capacity to explore the chemical space of proteins (57)
with several drugs developed through the use of FBDD
recently approved to treat cancer. Our work demonstrates
the potential of this technique to create new antibiotics,
with careful structure-guided optimisation of initial frag-
ment hits rapidly producing potent inhibitors with anti-
mycobacterial activity. Furthermore, our fragment screen-
ing revealed numerous other hits with diverse binding
modes, offering multiple possibilities for future compound
elaboration and optimization.
Mycobacteria are a notoriously difficult group of mi-
croorganisms to develop new drugs against, due to their
impermeable cell wall, efflux pumps, target modification
enzymes, and extensive capacity to metabolise compounds
(58). TrmD is a highly conserved enzyme in mycobacteria
(Supplementary Figure S11) and the M. abscessus TrmD
compounds developed in this study, not only showed po-
tent affinity toward M. tuberculosis TrmD but also were ac-
tive against several other mycobacteria, including M. lep-
rae. While we succeeded in developing potent TrmD in-
hibitors, the disconnect observed between compound affin-
ity in vitro and bacterial MIC for some of these molecules,
will require further iterative efforts to optimize permeabil-
ity, retention and/or intra-bacterial metabolic stability of
the compounds. It will be also interesting to probe the ef-
fect of the TrmD inhibitors developed in this study on mem-
8110 Nucleic Acids Research, 2020, Vol. 48, No. 14
Table 2. Minimum inhibitory concentration (MIC) values (M) of TrmD lead compounds across various mycobacterial species and strains
Compound M. abscessus M. tuberculosis M. chelonae M. fortuitum M. gordonae M. terrae M. avium
AW5 50 12.5 ND ND ND ND ND
AW6 50 6.3 100 100 100 100 200
AW7 50 6.3 100 100 100 25 100
Figure 5. (A) Growth inhibition study of lead compounds AW6 and AW7 in M. abscessus infected human macrophages over a 48 h period. The decrease in
CFU/ml following 48 h with 25M AW7 is statistically significant (P < 0.001) showing the cidality of AW7 for intracellular M. abscessus. (B) Intracellular
M. leprae palmitic acid oxidation rate (radiorespirometry) in the presence of different concentrations of AW7 for 7 days. Seventh day cumulative counts
per minute (CPM) were recorded and percentage inhibition of metabolism determined as compared to no drug control. AW7 concentrations, in mM, are
shown in parenthesis and rifampin (RMP) was used at 2.4 M. (C) Target engagement of AW7 with M. abscessus TrmD. Incremental silencing of trmD
using a CRISPR dCas9 tunable system further sensitises M. abscessus to AW7 while such effect is not observed for the empty vector or for another essential
gene yidC.
brane protein and efflux pump biosynthesis in mycobacte-
ria, as previously observed in gram-negative bacteria (15).
Such an effect, if also present in mycobacteria, could indi-
cate an additional role of TrmD inhibitors by way of sensi-
tizing mycobacteria towards antibiotics. Nevertheless, the
results of this study, with macrophage infection models,
the demonstrated on-target activity and the encouraging
preliminary cytotoxicity data, shows the potential of these
molecules to be further developed into novel mycobacterial
drugs.
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